吉利德科学 GILD 深 沪
等待开盘 06-26 09:30:00 美东时间
123.695
-1.455
-1.16%
华盛通- 最 高127.27
- 今 开125.26
- 成交量 497.44万股
- 最 低 123.00
- 昨 收 125.15
- 总市值 1.55亿
- 52周最高 157.29
- 市盈率 静 25.08
- 换手率 396.68%
- 52周最低 108.04
- 委 比 -3.88%
- 总股本 0.01亿
- 历史最高 157.29
- 量 比 0.49
- 振 幅 3.41%
- 历史最低 0.195
- 每 手 1
- 风险率 12.10%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Gilead And Merck End Trodelvy-Keytruda Lung Cancer Trial
Gilead And Merck Report Phase 3 HIV Trial Success As Separate Lung Cancer Study Of Trodelvy-Keytruda Combination Ends
06-10 01:44
康诺亚：首付款2.57亿美元已收到
2026年6月5日，康诺亚宣布，公司NewCo合作企业Ouro Medicines已被吉利德和Lakefront Biotherapeutics NV成功收购...
06-08 13:18
Sanofi-Owkin Expand AI Collaboration With New Agentic AI Initiative
Owkin and Sanofi expand their AI partnership with a five-year deal to develop agentic systems aimed at accelerating drug research.
06-05 19:01
Gilead Backs South Africa, Global Fund Push for HIV Prevention Drug Access
Gilead applauds the leadership of the Government of South Africa and the Global Fund for accelerating access to lenacapavir, a long-acting HIV prevention medication. This marks an important step toward expanding access
06-05 15:54
Gilead Advances Liver Disease Ambitions With Encouraging Study Outcome
Gilead reports positive Phase 3 Livdelzi data in PBC, with more patients achieving ALP normalization versus placebo after 52 weeks.
06-03 01:47
FDA Approves First Treatment For Chronic Hepatitis Delta Virus (HDV) Infection
https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-chronic-hepatitis-delta-virus-hdv-infection
05-23 01:38
Nasdaq Tops 29,000 Records, Micron Soars 13%: Stock Market Today
Nasdaq jumps 1.6% to record highs Friday as semiconductor rally and stronger-than-expected April payrolls overshadow ongoing Strait of Hormuz tensions.
05-09 01:36
Kailera Therapeutics' Strong IPO Validates "NewCo" Strategy
A company set up to develop Hengrui Pharma's weight-loss drugs has made a stron...
04-24 00:08
Gilead Sciences Receives All Required Regulatory Approvals To Acquire Arcellx At $115/Share
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that all required regulatory approvals have been obtained for its previously announced acquisition of Arcellx and that Gilead has extended the expiration of the tender
04-17 20:31
